Quick follow-up on something I wrote about last week, because the market went and did exactly what I suspected. Moderna's stock has more than doubled, adding roughly $30 billion in equity value, after a trial showed its experimental melanoma vaccine prevented recurrence in patients. Reuters' Breakingviews column ran the numbers and the conclusion is stark: a gain that size isn't about one successful drug, it's investors assuming this platform works against many cancers.

Let's do the arithmetic the way the column does. A melanoma drug, even a very good one, has a finite market. Melanoma is serious but it's a fraction of the cancer landscape. If Moderna's market cap jumped $30 billion on melanoma data alone, the price-to-earnings math stops working. What you're actually buying at that valuation is the assumption that the same mRNA-plus-personalized-antigen approach, the machinery that made the COVID vaccine and now this, generalizes to pancreatic, lung, colorectal, and whatever else is sitting in the pipeline.

That's the bet. It's a big one.

Here's my developer brain on this: the market is treating melanoma like a passing test suite and assuming the whole codebase is production-ready. But melanoma is famously immunogenic, meaning it's the tumor type most likely to respond to anything that revs up the immune system. It's the happy path. Pancreatic cancer, by contrast, builds a fortress of tissue that immune cells struggle to penetrate. It's the edge case that eats your weekend.

As I said when Moderna's jump first hit, I think the market is ignoring how hard it is to scale this platform beyond the happy path. Each cancer type has its own mutation profile, its own immune evasion tricks, its own tumor microenvironment. A personalized vaccine pipeline that works cleanly for melanoma doesn't automatically port to a dozen other indications... it means running expensive, years-long trials for each one, with real failure risk baked into every single one.

None of this is a knock on the science. Preventing recurrence in melanoma patients with a customized vaccine is a genuine breakthrough, the kind of thing that would have sounded like science fiction when I was in high school. Sequencing a patient's tumor, identifying neoantigens, manufacturing a bespoke mRNA vaccine, and training the immune system to hunt down the remaining cancer cells, that's an incredible stack.

But incredible tech and sound valuation are different columns. Reuters frames it well: the current price implies many cancer successes, plural, most of which haven't happened yet and some of which won't. And if the next readout stumbles, a lot of that $30 billion evaporates faster than it arrived.

I'll keep watching the trial pipeline the way I watch a slow CI run: optimistic, but I know how often the build breaks at 90%.